[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015031417A8 - forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem - Google Patents

forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem

Info

Publication number
BR112015031417A8
BR112015031417A8 BR112015031417A BR112015031417A BR112015031417A8 BR 112015031417 A8 BR112015031417 A8 BR 112015031417A8 BR 112015031417 A BR112015031417 A BR 112015031417A BR 112015031417 A BR112015031417 A BR 112015031417A BR 112015031417 A8 BR112015031417 A8 BR 112015031417A8
Authority
BR
Brazil
Prior art keywords
dosage form
pharmaceutical
cysteamine
preparing
patient
Prior art date
Application number
BR112015031417A
Other languages
English (en)
Other versions
BR112015031417B1 (pt
BR112015031417A2 (pt
Inventor
Powell Kathlene
Muttavarapu Ramesh
Dohil Ranjan
Original Assignee
Horizon Orphan Llc
Raptor Pharmaceuticals Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52019418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031417(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Orphan Llc, Raptor Pharmaceuticals Inc, Univ California filed Critical Horizon Orphan Llc
Publication of BR112015031417A2 publication Critical patent/BR112015031417A2/pt
Publication of BR112015031417A8 publication Critical patent/BR112015031417A8/pt
Publication of BR112015031417B1 publication Critical patent/BR112015031417B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Fodder In General (AREA)

Abstract

forma de dosagem farmacêutica, uso de uma forma de dosagem farmacêutica, e método para preparo de uma forma de dosagem farmacêutica. a presente invenção se refere a uma forma de dosagem de grânulo com revestimento entérico de cisteamina e métodos relacionados de fabricação e uso.
BR112015031417-1A 2013-06-17 2014-06-17 Forma de dosagem farmacêutica BR112015031417B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835965P 2013-06-17 2013-06-17
US61/835,965 2013-06-17
PCT/US2014/042607 WO2014204881A1 (en) 2013-06-17 2014-06-17 Delayed release cysteamine bead formulation

Publications (3)

Publication Number Publication Date
BR112015031417A2 BR112015031417A2 (pt) 2017-07-25
BR112015031417A8 true BR112015031417A8 (pt) 2021-06-22
BR112015031417B1 BR112015031417B1 (pt) 2022-12-27

Family

ID=52019418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031417-1A BR112015031417B1 (pt) 2013-06-17 2014-06-17 Forma de dosagem farmacêutica

Country Status (25)

Country Link
US (9) US9233077B2 (pt)
EP (2) EP3010491A4 (pt)
JP (1) JP6468661B2 (pt)
KR (2) KR102466253B1 (pt)
CN (2) CN105492000B (pt)
AP (1) AP2015008925A0 (pt)
AR (2) AR096628A1 (pt)
AU (1) AU2014281702C1 (pt)
BR (1) BR112015031417B1 (pt)
CA (2) CA2938644C (pt)
CL (1) CL2015003662A1 (pt)
CU (1) CU20150178A7 (pt)
EA (1) EA031255B8 (pt)
HK (1) HK1218066A1 (pt)
IL (2) IL302141A (pt)
MX (1) MX2015017366A (pt)
NI (1) NI201500177A (pt)
NZ (1) NZ714517A (pt)
PH (1) PH12015502783A1 (pt)
SG (1) SG11201510126QA (pt)
TN (1) TN2015000549A1 (pt)
TW (1) TWI649100B (pt)
UA (1) UA117833C2 (pt)
WO (1) WO2014204881A1 (pt)
ZA (1) ZA201508783B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096629A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Métodos para analizar composiciones de cisteamina
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
ITUA20161799A1 (it) 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
SG11201908457WA (en) * 2017-03-15 2019-10-30 Cerecin Inc Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
WO2023249087A1 (ja) * 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
AU2002352982B2 (en) 2001-11-29 2008-03-06 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DK1471902T3 (da) 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CN100391448C (zh) 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
TWI350751B (en) 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CA2565250C (en) 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
KR20070119658A (ko) * 2005-03-29 2007-12-20 에보니크 룀 게엠베하 활성 성분 방출에 대한 조절 효과를 가지는 물질을포함하는 펠렛을 포함하는 다중 미립자 제약 형태
AU2006236150A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
AU2007210005C1 (en) 2006-01-27 2014-01-23 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
ES2417179T3 (es) 2007-11-30 2013-08-06 The Regents Of The University Of California Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina
CN102006785A (zh) 2008-02-17 2011-04-06 华扩达动物科学(I.P.3)有限公司 改善虾健康的材料和方法
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
ES2624719T3 (es) * 2009-03-18 2017-07-17 Evonik Röhm Gmbh Composición farmacéutica de liberación controlada con resistencia contra la influencia del etanol empleando un recubrimiento que comprende polímeros de vinilo neutros y excipientes
CN101653426A (zh) 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
CN101703472B (zh) * 2009-11-09 2011-06-22 上海邦成生物科技有限公司 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法
CN102077905B (zh) 2010-12-10 2013-01-02 无锡正大畜禽有限公司 一种肠溶盐酸半胱胺包膜颗粒的生产方法
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
MX2014004469A (es) * 2011-11-22 2014-08-01 Univ California Metodos y composiciones para tratar inflamacion y lesion isquemica.
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Also Published As

Publication number Publication date
EA031255B1 (ru) 2018-12-28
US20160095827A1 (en) 2016-04-07
KR20160045053A (ko) 2016-04-26
CA2938644A1 (en) 2014-12-24
CN110664780B (zh) 2022-09-27
AU2014281702C1 (en) 2020-05-14
US20140370085A1 (en) 2014-12-18
IL284823A (en) 2021-08-31
NI201500177A (es) 2016-02-15
JP2016523250A (ja) 2016-08-08
US20170319514A1 (en) 2017-11-09
IL302141A (en) 2023-06-01
TN2015000549A1 (en) 2017-04-06
AR096628A1 (es) 2016-01-20
ZA201508783B (en) 2019-09-25
UA117833C2 (uk) 2018-10-10
CA2914770A1 (en) 2014-12-24
EA031255B8 (ru) 2019-11-29
AU2014281702B2 (en) 2019-11-07
US20170319513A1 (en) 2017-11-09
AR128816A2 (es) 2024-06-19
US20160158170A1 (en) 2016-06-09
BR112015031417B1 (pt) 2022-12-27
TWI649100B (zh) 2019-02-01
JP6468661B2 (ja) 2019-02-13
SG11201510126QA (en) 2016-01-28
EA201690036A1 (ru) 2016-09-30
TW201534357A (zh) 2015-09-16
US20160331704A1 (en) 2016-11-17
MX2015017366A (es) 2016-07-13
WO2014204881A8 (en) 2016-02-18
KR102281747B1 (ko) 2021-07-26
US20190298665A1 (en) 2019-10-03
US9173851B1 (en) 2015-11-03
KR102466253B1 (ko) 2022-11-10
KR20210094140A (ko) 2021-07-28
CN105492000A (zh) 2016-04-13
CA2914770C (en) 2016-09-27
US9233077B2 (en) 2016-01-12
NZ714517A (en) 2018-10-26
EP3010491A4 (en) 2016-05-18
US11090279B2 (en) 2021-08-17
PH12015502783A1 (en) 2016-03-21
CU20150178A7 (es) 2016-07-29
CN110664780A (zh) 2020-01-10
AP2015008925A0 (en) 2015-12-31
EP3010491A1 (en) 2016-04-27
CL2015003662A1 (es) 2016-08-05
WO2014204881A1 (en) 2014-12-24
CA2938644C (en) 2019-08-27
BR112015031417A2 (pt) 2017-07-25
HK1218066A1 (zh) 2017-02-03
US20150290139A1 (en) 2015-10-15
CN105492000B (zh) 2019-11-15
US20170319512A1 (en) 2017-11-09
AU2014281702A1 (en) 2015-12-10
EP3939574A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
DK3068392T3 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
HRP20181872T1 (hr) Derivati tamoksifena za liječenje neoplastičnih bolesti, posebice s višom razinom proteina her2
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
IL240731B (en) An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi
EP3311809A4 (en) USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
FI20136136A (fi) Menetelmä kosmeettisten koostumusten valmistamiseksi, kosmeettiset koostumukset sekä niiden käyttö
IN2013MU03428A (pt)
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания
BR112015031258A2 (pt) método de produção de uma composição líquida estruturada, composição líquida estruturada, produto para tratamento de transpiração e uso de um líquido estruturado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HORIZON ORPHAN LLC (US)

B25G Requested change of headquarter approved

Owner name: HORIZON ORPHAN LLC (US)

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ;

Free format text: RETIFICACAO DO DESPACHO 25.1 ? TRANSFERENCIA DE TITULAR PUBLICADO NA RPI NO 2539, DE 03/09/2019, QUANTO AO ITEM 71 ? DEPOSITANTE, VISTO QUE TRATAVA-SE DE UMA TRANSFERENCIA PARCIAL.ONDE SE LE: THE REGENTS OF THE UNIVERSITY OF CALIFORNIALEIA-SE: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA E HORIZON ORPHAN LLC.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2014, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; HORIZON THERAPEUTICS U.S. HOLDING LLC (US)